Achilles Therapeutics (ACHL)
(Delayed Data from NSDQ)
$0.94 USD
+0.23 (32.39%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $0.94 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Achilles Therapeutics PLC Sponsored ADR (ACHL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$2.83 | $6.00 | $0.50 | 298.59% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Achilles Therapeutics PLC Sponsored ADR comes to $2.83. The forecasts range from a low of $0.50 to a high of $6.00. The average price target represents an increase of 298.59% from the last closing price of $0.71.
Analyst Price Targets (3 )
Broker Rating
Achilles Therapeutics PLC Sponsored ADR currently has an average brokerage recommendation (ABR) of 2.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 2.67 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, one is Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/5/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
4/5/2024 | Piper Sandler | Joseph M Catanzaro | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.67 |
ABR (Last week) | 2.67 |
# of Recs in ABR | 3 |
Average Target Price | $2.83 |
LT Growth Rate | 59.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -0.41 |
ACHL FAQs
Achilles Therapeutics PLC Sponsored ADR (ACHL) currently has an average brokerage recommendation (ABR) of 2.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 3 brokerage firms.
The average price target for Achilles Therapeutics PLC Sponsored ADR (ACHL) is $2.83. The current on short-term price targets is based on 3 reports.
The forecasts for Achilles Therapeutics PLC Sponsored ADR (ACHL) range from a low of $.5 to a high of $6. The average price target represents a increase of $201.06 from the last closing price of $.94.
The current UPSIDE for Achilles Therapeutics PLC Sponsored ADR (ACHL) is 201.06%
Based on short-term price targets offered by three analysts, the average price target for Achilles Therapeutics PLC Sponsored ADR comes to $2.83. The forecasts range from a low of $0.50 to a high of $6.00. The average price target represents an increase of 298.59% from the last closing price of $0.71.